248 related articles for article (PubMed ID: 26765315)
1. Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Ally MS; Ransohoff K; Sarin K; Atwood SX; Rezaee M; Bailey-Healy I; Kim J; Beachy PA; Chang AL; Oro A; Tang JY; Colevas AD
JAMA Dermatol; 2016 Apr; 152(4):452-6. PubMed ID: 26765315
[TBL] [Abstract][Full Text] [Related]
2. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.
Kim DJ; Kim J; Spaunhurst K; Montoya J; Khodosh R; Chandra K; Fu T; Gilliam A; Molgo M; Beachy PA; Tang JY
J Clin Oncol; 2014 Mar; 32(8):745-51. PubMed ID: 24493717
[TBL] [Abstract][Full Text] [Related]
3. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
4. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
[TBL] [Abstract][Full Text] [Related]
5. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM
Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
Von Hoff DD; LoRusso PM; Rudin CM; Reddy JC; Yauch RL; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Mackey HM; Lum BL; Darbonne WC; Marsters JC; de Sauvage FJ; Low JA
N Engl J Med; 2009 Sep; 361(12):1164-72. PubMed ID: 19726763
[TBL] [Abstract][Full Text] [Related]
8. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
[TBL] [Abstract][Full Text] [Related]
9. Expression profile of sonic hedgehog signaling-related molecules in basal cell carcinoma.
Kim HS; Kim YS; Lee C; Shin MS; Kim JW; Jang BG
PLoS One; 2019; 14(11):e0225511. PubMed ID: 31756206
[TBL] [Abstract][Full Text] [Related]
10. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
11. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide inhibits the Hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia.
Yang D; Cao F; Ye X; Zhao H; Liu X; Li Y; Shi C; Wang H; Zhou J
Acta Haematol; 2013; 130(4):260-7. PubMed ID: 23867347
[TBL] [Abstract][Full Text] [Related]
13. A Novel Mechanism for Activation of GLI1 by Nuclear SMO That Escapes Anti-SMO Inhibitors.
Rahman MM; Hazan A; Selway JL; Herath DS; Harwood CA; Pirzado MS; Atkar R; Kelsell DP; Linton KJ; Philpott MP; Neill GW
Cancer Res; 2018 May; 78(10):2577-2588. PubMed ID: 29463581
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.
Chen B; Trang V; Lee A; Williams NS; Wilson AN; Epstein EH; Tang JY; Kim J
Mol Cancer Ther; 2016 May; 15(5):866-76. PubMed ID: 26823493
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin.
Makinodan E; Marneros AG
Exp Dermatol; 2012 Nov; 21(11):847-52. PubMed ID: 23163650
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
[TBL] [Abstract][Full Text] [Related]
19. [Synergistic Killing Effects of Arsenic Trioxide Combined with Itraconazole on KG1a Cells].
Wu JW; Xiao WT; Zeng YJ; Fan JX; Ye YB; Li YM; Zhen R; Guo KY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1003-1010. PubMed ID: 28823259
[TBL] [Abstract][Full Text] [Related]
20. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
